Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SAN DIEGO, Aug. 10, 2017 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, will report its financial results for the second quarter 2017 after the U.S. financial markets close on Monday, August 14, 2017.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163
